Eli Lilly, Sanford-Burnham collaborate to investigate immunological therapies
Eli Lilly and Sanford-Burnham Medical Research Institute, a nonprofit medical research institute based in Florida, are collaborating to discover and develop immunological therapies. The company will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.
The comprehensive research collaboration is driven by Eli Lilly's biotechnology capabilities and immunology experience, and Sanford-Burnham's experience in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F. Bumol, Ph.D., senior vice president, biotechnology and immunology research at Eli Lilly, and Carl Ware, Ph.D., director, Infectious and Inflammatory Diseases Center at Sanford-Burnham.
"The Lilly-Sanford-Burnham collaboration is precedent setting in scope and its potential to advance discoveries to the patient more efficiently," said Sanford-Burnham CEO Perry Nisen, M.D., Ph.D. "By combining the deep knowledge of human biology and disease mechanisms among Sanford-Burnham scientists, in particular our expertise in the field of checkpoint regulators in the immune system, and Lilly's leadership position in the development of biologics and large molecules, we are forging the path to develop the next generation of transformative treatments for autoimmune disease."